newsfilter
← Latest News
GlobeNewswire·

TCR² Therapeutics Reviews Pipeline and Strategy at R&D Day

- gavo-cel recommended Phase 2 dose (RP2D) identification before year-end - Anticipated IND filing for TC-510 in 1Q22 - Identification of CD70-targeted lead candidate - Anticipated allogeneic program lead candidate in 2022 - Expansion of plat